Skip to content

IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP

IL37,Tlymphocytes ,NK Cells in Pathogenesis of Immune Thrombocytopenia.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04482777
Enrollment
90
Registered
2020-07-23
Start date
2023-07-30
Completion date
2023-09-01
Last updated
2023-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ITP

Brief summary

To evaluate the role of IL37 in pathogenesis of ITP and to study the relation between IL37,Tlymphocytes,NK cells in ITP

Detailed description

Idiopathic thrombocytopenia or immune thrombocytopenia (ITP) is a hematological condition which is characterized by a low platelet count of less than 100 x 109L . Symptoms of ITP can vary but tend to be symptoms of thrombocytopenia in general, such as petechiae, purpura, mucosal bleeding and in the most severe cases fatal intracranial hemorrhage(1,2) Interleukin (IL)-37, a novel anti-inflammatory cytokine previously known as interleukin-1 family member 7 before it was renamed, has a pivotal role in the suppression of immune responses (3,4). IL-37 is widely expressed in several types of cells, tissues and organs, including peripheral blood mononuclear cells (PBMCs) (5). The major role of IL-37 is to decrease excessive inflammation in innate and adaptive immune diseases, mainly by inhibiting the expression, production and function of pro-inflammatory cytokines, including IL-1α, IL-6, tumor necrosis factor (TNF) and macrophage inflammatory protein-2. The abundance of these cytokines has been reported to increase with the silencing of endogenous IL-37 in human blood cells (3,6).Aberrant expression of IL-37 has been observed in several inflammatory and autoimmune diseases However, the role of IL-37 in ITP has remained elusive. Immune thrombocytopenia pathogenesis is a complicated process. T cell immune abnormalities are involved in ITP pathogenesis. These abnormalities include platelet auto-antigen reactive cytotoxic T cells, abnormal numbers and functions of T regulatory cells, loss of Th1/Th2 balance, megakaryocyte maturation abnormalities and abnormal T cell anergy.

Interventions

DRUGCorticosteriod for treated patients

Drug given to some patients with autoimmune disease

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 60 Years

Inclusion criteria

* Patients with ITP (moderate and sever) different age group.

Exclusion criteria

* Patients with stroke and myocardial infarction,malignant tumors or pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
To decrease the immunity complications in ITP patientsBaselineEarly detection of immunity complications in ITP patients
To decrease case fatality rateBaselineEarly detection of immunity complication will decrease mortality rate

Contacts

Primary ContactAsmaa Mohamed
mohamedasmaa550@yahoo.com01027575354
Backup ContactMarwa Mohamed
01092288360

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026